PT - JOURNAL ARTICLE AU - Chang Yi Wang AU - Kao-Pin Hwang AU - Hui-Kai Kuo AU - Be-Sheng Kuo AU - Hope Liu AU - Kuo-Liang Hou AU - Wan-Yu Tsai AU - Han-Chen Chiu AU - Yu-Hsin Ho AU - Jennifer Cheng AU - Min-Sheng Wang AU - Ya-Ting Yang AU - Po-Yen Chang AU - Yea-Huei Shen AU - Wen-Jiun Peng TI - UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern AID - 10.1101/2022.04.11.22272364 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.11.22272364 4099 - http://medrxiv.org/content/early/2022/05/05/2022.04.11.22272364.short 4100 - http://medrxiv.org/content/early/2022/05/05/2022.04.11.22272364.full AB - Importance The SARS-CoV-2 non-spike structural proteins of nucleocapsid (N), membrane (M) and envelope (E) are critical in the host cell interferon response and memory T-cell immunity and have been grossly overlooked in the development of COVID vaccines.Objective To determine the safety and immunogenicity of UB-612, a multitope vaccine containing S1-RBD-sFc protein and rationally-designed promiscuous peptides representing sequence-conserved Th and CTL epitopes on the Sarbecovirus nucleocapsid (N), membrane (M) and spike (S2) proteins.Design, setting and participants UB-612 booster vaccination was conducted in Taiwan. A UB-612 booster dose was administered 6-8 months post-2nd dose in 1,478 vaccinees from 3,844 healthy participants (aged 18-85 years) who completed a prior placebo (saline)-controlled, randomized, observer-blind, multi-center Phase-2 primary 2-dose series (100-μg per dose; 28-day apart) of UB-612. The interim safety and immunogenicity were evaluated until 14 days post-booster.Exposure Vaccination with a booster 3rd-dose (100-μg) of UB-612 vaccine.Main outcomes and measures Solicited local and systemic AEs were recorded for seven days in the e-diaries of study participants, while skin allergic reactions were recorded for fourteen days. The primary immunogenicity endpoints included viral-neutralizing antibodies against live SARS-CoV-2 wild-type (WT, Wuhan strain) and live Delta variant (VNT50), and against pseudovirus WT and Omicron variant (pVNT50). The secondary immunogenicity endpoints included anti-S1-RBD IgG antibody, S1-RBD:ACE2 binding inhibition, and T-cell responses by ELISpot and Intracellular Staining.Results No post-booster vaccine-related serious adverse events were recorded. The most common solicited adverse events were injection site pain and fatigue, mostly mild and transient. The UB-612 booster prompted a striking upsurge of neutralizing antibodies against live WT Wuhan strain (VNT50, 1,711) associated with unusually high cross-neutralization against Delta variant (VNT50, 1,282); and similarly with a strong effect against pseudovirus WT (pVNT50, 6,245) and Omicron variant (pVNT50, 1,196). Upon boosting, the lower VNT50 and pVNT50 titers of the elderly in the primary series were uplifted to the same levels as those of the young adults. The UB-612 also induced robust, durable VoC antigen-specific Th1-oriented (IFN-γ+-) responses along with CD8+ T-cell (CD107a+-Granzyme B+) cytotoxicity.Conclusions and relevance With a pronounced cross-reactive booster effect on B- and T-cell immunity, UB-612 may serve as a universal vaccine booster for comprehensive immunity enhancement against emergent VoCs.Trial registration [ClinicalTrials.gov: NCT04773067]Question Facing ever-emergent SARS-CoV-2 variants and long-haul COVID, can composition-updated new vaccines be constructed capable of inducing striking, durable booster-recalled B/T-immunity to prevent infection by VoCs?Findings In a Phase-2 extension study, a booster dose of UB-612 multitope protein-peptide vaccine prompted high viral-neutralizing titers against live wild-type virus (VNT50, 1,711), Delta variant (VNT50, 1,282); pseudovirus wild-type (pVNT50, 6,245) and Omicron variant (pVNT50, 1,196). Robust, durable Th1-IFNγ+ responses and CD8+ T cell-(CD107a+-Granzyme B+) cytotoxic activity were both observed.Meaning UB-612 RBD-sFc vaccine armed with T cell immunity-promoting conserved N, M and S2 Th/CTL epitope peptides may serve as a universal vaccine to fend off new VoCs.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04773067Funding StatementUBI Asia (study sponsor) and the Taiwan Centers for Disease Control, Ministry of Health and Welfare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted at China Medical University Hospital, Taiwan; the Institutional Review Board of the study site and the Taiwan Food and Drug Administration approved the design of the study and the contents of the informed consent form and openly available at these sites.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://unitedbiomedical.com